About Link Pharma
Link Pharma is a publicly listed company based in Vadodara (India) founded in 1986. Developing and manufacturing services for APIs and specialty chemicals. The company has 83 employees. Its chief executive, as recorded, is Satish Thakur. Its Indian entity Link Pharmachem Limited reported revenue of ₹27.63 Cr. Link Pharma offers products and services including Pharma Intermediates, Agro Intermediates, Veterny Intermediates, Cosmetics Intermediates, and Fragrance Intermediates. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and API Production. Similar companies include Laurus Labs, Symbiotec and SeQuent; 2 of its 3 listed similar companies have raised funding.
Company details
Link Pharma was established in 1986 in Vadodara, India, within the chemical and pharmaceutical sector. Active pharmaceutical ingredients (APIs) and specialty chemicals are developed and manufactured by the company. Operations include production of compounds such as chlorine, oleum, chlorosulphonic acid, sulphuric acid, and sulfur chlorides. Services focus on these areas to support industrial needs in the region.
- Headquarters Vadodara, India
- Employees 83
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website linkpharmachem.co.in
- Social LinkedIn
- Legal Name Link Pharma Chem Ltd.
- Market Cap₹10.77 Cr
LINKPH · BSE
- Share Price₹26.00
+7.22% today
- Revenue₹27.43 Cr
FY 2025-26 · +7.9% YoY
- EBITDA₹1.44 Cr
Margin 5.2%
- Net Profit₹0.07 Cr
FY 2025-26 · +106.7% YoY
- ROE0.6%
ROCE 3.4%
- Debt / Equity0.51
Interest cover 115.2x
- Employee Count83
Associated legal entities of Link Pharma
Link Pharma operates through Link Pharmachem Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Link Pharmachem Limited Listed CIN L24230GJ1984PLC007540 | Active | 28 Dec 1984 | Vadodara, Gujarat | ₹27.6 Cr | 84 | 7 | View details |
Products & Services of Link Pharma
Link Pharma offers a comprehensive portfolio of products and services, including Pharma Intermediates, Agro Intermediates, Veterny Intermediates, Cosmetics Intermediates, and Fragrance Intermediates.
Intermediates for pharmaceutical production and export.
Intermediates for agro industries and farming applications.
Intermediates for veterinary and related chemical uses.
Intermediates for cosmetics manufacturing and export.
Intermediates for fragrance production and specialty applications.
Board of directors of Link Pharmachem Limited (Link Pharma)
Link Pharmachem Limited is the primary company behind Link Pharma. The board of Link Pharmachem Limited currently have 5 directors; the longest-serving is Satish Ganpatrao Thakur, appointed in 1984. 11 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Satish Ganpatrao Thakur DIN 00292129 | Whole-time director | 28 Dec 1984 | 41 yrs 9 mo | Link Pharmachem Limited |
| Rishikesh Satish Thakur DIN 08777265 | Managing Director | 24 Jun 2020 | 6 yrs 4 mo | Link Pharmachem Limited |
| Rachna Manav Ghai DIN 08885422 | Director | 14 Sep 2020 | 6 yrs 1 mo | Link Pharmachem Limited |
| Rohit Jitendraprasad Shah DIN 06885402 | Director | 09 Aug 2024 | 2 yrs 2 mo | Link Pharmachem Limited |
| Rangoli Saurav Gada DIN 10109783 | Director | 09 Aug 2024 | 2 yrs 2 mo | Link Pharmachem Limited |
People of Link Pharma
2 people are tracked at Link Pharma (2 in leadership); the tracked headcount is 83.
| Name | Role | Group |
|---|---|---|
| Co-CEO | Leadership | |
| Co-CEO | Leadership |
Complete people profiles for Link Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Link Pharma
Link Pharma is a publicly listed company on the BSE with ticker symbol LINKPH in India, operating in the Process industries sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date02 Jun 1995
- Listed onBSE: 524748
- Listed entityLink Pharma Chem Ltd.
- Exchange sectorProcess industries
- ISININE302F01011
- Share price₹26.99 (-0.04% on the day) · 2026-10-14
- Market capitalisation₹12.0 Cr
- EPS (diluted, trailing year)₹-0.01
- Volume (last session)608
Financials of Link Pharma
Exchange-reported figures of Link Pharmachem Limited, the listed company behind Link Pharma (BSE: LINKPH).
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 27.43 | 25.43 | 29.90 | 38.76 | 53.56 | 34.81 | 25.47 |
| Revenue growth | +7.9% | -15.0% | -22.9% | -27.6% | +53.9% | +36.7% | - |
| EBITDA | 1.44 | 0.11 | (0.65) | 2.72 | 3.53 | 2.98 | 2.60 |
| EBITDA margin | +5.3% | +0.4% | -2.2% | +7.0% | +6.6% | +8.6% | +10.2% |
| Profit before tax | 0.13 | (1.42) | (1.91) | 0.89 | 2.61 | 1.69 | 1.44 |
| Net profit | 0.07 | (1.05) | (1.44) | 0.57 | 1.43 | 1.23 | 1.61 |
| Net profit margin | +0.3% | -4.1% | -4.8% | +1.5% | +2.7% | +3.5% | +6.3% |
| EPS (₹) | 0.17 | (2.31) | (3.07) | 1.47 | 4.24 | 2.44 | 2.14 |
| Balance sheet | |||||||
| Total assets | 20.33 | 18.61 | 22.93 | 24.00 | 20.90 | 16.40 | 14.99 |
| Net worth | 12.79 | 12.66 | 13.71 | 15.04 | 14.47 | 12.56 | 11.43 |
| Total debt | 7.31 | 5.78 | 9.22 | 8.76 | 6.39 | 3.66 | 3.56 |
| Cash & bank | 0.63 | 0.06 | 0.09 | 0.20 | 0.88 | 4.86 | 2.05 |
| Net working capital | 6.70 | 6.48 | 8.69 | 9.81 | 6.46 | 6.37 | 6.02 |
| Cash flow | |||||||
| Cash from operations | 2.15 | 2.69 | (0.03) | (1.71) | (1.26) | 4.84 | 2.95 |
| Cash from investing | (2.66) | 1.53 | 0.41 | (0.08) | (4.97) | (2.16) | (1.66) |
| Cash from financing | 0.99 | (4.21) | (0.41) | 1.61 | 2.27 | (0.33) | 0.55 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 8.77 | 6.59 | 6.73 | 6.29 | 7.81 | 6.45 | 5.34 | 4.80 |
| Revenue growth (YoY) | +12.3% | +2.2% | +26.0% | +31.0% | -11.8% | - | - | - |
| Other income | 0.35 | 0.15 | (0.20) | 0.05 | 0.21 | 0.12 | (0.56) | 0.36 |
| Total expenses | 8.31 | 6.83 | 6.04 | 5.95 | 7.17 | 6.67 | 5.23 | 5.10 |
| EBITDA | 0.46 | (0.24) | 0.69 | 0.34 | 0.64 | (0.22) | 0.11 | (0.30) |
| EBITDA margin | +5.2% | -3.6% | +10.3% | +5.4% | +8.2% | -3.4% | +2.1% | -6.3% |
| Depreciation | 0.27 | 0.25 | 0.25 | 0.25 | 0.24 | 0.24 | 0.24 | 0.24 |
| Interest | 0.14 | 0.15 | 0.14 | 0.13 | 0.10 | 0.14 | 0.21 | 0.21 |
| Profit before tax | 0.40 | (0.49) | 0.10 | 0.01 | 0.51 | (0.48) | (0.90) | (0.39) |
| Tax | 0.07 | (0.08) | 0.04 | 0.00 | 0.11 | (0.13) | (0.22) | (0.08) |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 8.77 | 6.59 | 6.73 | 6.29 | 7.81 | 6.45 | 5.34 | 4.80 |
| Revenue growth (YoY) | +12.3% | +2.2% | +26.0% | +31.0% | -11.8% | - | - | - |
| Other income | 0.35 | 0.15 | (0.20) | 0.05 | 0.21 | 0.12 | (0.56) | 0.36 |
| Total expenses | 8.31 | 6.83 | 6.04 | 5.95 | 7.17 | 6.67 | 5.23 | 5.10 |
| EBITDA | 0.46 | (0.24) | 0.69 | 0.34 | 0.64 | (0.22) | 0.11 | (0.30) |
| EBITDA margin | +5.2% | -3.6% | +10.3% | +5.4% | +8.2% | -3.4% | +2.1% | -6.3% |
| Depreciation | 0.27 | 0.25 | 0.25 | 0.25 | 0.24 | 0.24 | 0.24 | 0.24 |
| Interest | 0.14 | 0.15 | 0.14 | 0.13 | 0.10 | 0.14 | 0.21 | 0.21 |
| Profit before tax | 0.40 | (0.49) | 0.10 | 0.01 | 0.51 | (0.48) | (0.90) | (0.39) |
| Tax | 0.07 | (0.08) | 0.04 | 0.00 | 0.11 | (0.13) | (0.22) | (0.08) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 27.43 | 25.43 | 29.90 | 38.76 | 53.56 | 34.81 | 25.47 |
| Revenue growth | +7.9% | -15.0% | -22.9% | -27.6% | +53.9% | +36.7% | - |
| Other income | 0.20 | 0.19 | 0.64 | (0.15) | 0.46 | 0.02 | 0.13 |
| Total expenses | 25.99 | 25.32 | 30.55 | 36.04 | 50.03 | 31.83 | 22.87 |
| Employee cost | 6.09 | 5.39 | 5.52 | 5.69 | 5.77 | 5.63 | 4.99 |
| EBITDA | 1.44 | 0.11 | (0.65) | 2.72 | 3.53 | 2.98 | 2.60 |
| EBITDA margin | +5.3% | +0.4% | -2.2% | +7.0% | +6.6% | +8.6% | +10.2% |
| Depreciation | 0.98 | 0.94 | 1.03 | 0.92 | 0.93 | 0.87 | 0.93 |
| Interest | 0.53 | 0.78 | 0.87 | 0.76 | 0.45 | 0.44 | 0.36 |
| Profit before tax | 0.13 | (1.42) | (1.91) | 0.89 | 2.61 | 1.69 | 1.44 |
| Tax | 0.06 | (0.37) | (0.55) | 0.24 | 0.74 | 0.59 | 0.49 |
| Net profit | 0.07 | (1.05) | (1.44) | 0.57 | 1.43 | 1.23 | 1.61 |
| Net profit margin | +0.3% | -4.1% | -4.8% | +1.5% | +2.7% | +3.5% | +6.3% |
| EPS (₹) | 0.17 | (2.31) | (3.07) | 1.47 | 4.24 | 2.44 | 2.14 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 4.44 | 4.44 | 4.44 | 4.44 | 4.44 | 4.44 | 4.44 |
| Reserves & surplus | 8.35 | 8.22 | 9.27 | 10.60 | 10.03 | 8.12 | 6.99 |
| Shareholders' funds (net worth) | 12.79 | 12.66 | 13.71 | 15.04 | 14.47 | 12.56 | 11.43 |
| Secured loans | 1.04 | 0.66 | 1.40 | 1.98 | 2.90 | 3.16 | 3.17 |
| Unsecured loans | 6.27 | 5.12 | 7.82 | 6.78 | 3.49 | 0.50 | 0.39 |
| Total debt | 7.31 | 5.78 | 9.22 | 8.76 | 6.39 | 3.66 | 3.56 |
| Total liabilities | 20.33 | 18.61 | 22.93 | 24.00 | 20.90 | 16.40 | 14.99 |
| Assets | |||||||
| Gross block | 18.01 | 15.95 | 15.66 | 13.88 | 12.74 | 11.74 | 11.56 |
| Net block | 10.38 | 9.28 | 9.93 | 9.00 | 8.79 | 8.71 | 8.80 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.21 | 0.00 | 0.00 |
| Investments | 2.47 | 2.06 | 2.93 | 3.64 | 4.52 | 0.03 | 0.03 |
| Inventories | 5.02 | 5.74 | 6.21 | 12.25 | 4.76 | 2.50 | 1.63 |
| Sundry debtors | 5.28 | 5.02 | 5.15 | 3.63 | 5.37 | 5.55 | 4.99 |
| Cash & bank balances | 0.63 | 0.06 | 0.09 | 0.20 | 0.88 | 4.86 | 2.05 |
| Loans & advances | 0.41 | 0.34 | 0.08 | 1.47 | 2.57 | 2.24 | 0.41 |
| Total current assets | 11.34 | 11.16 | 11.53 | 17.55 | 13.58 | 15.15 | 9.08 |
| Total current liabilities | 4.64 | 4.68 | 2.84 | 7.74 | 7.12 | 8.78 | 3.06 |
| Net working capital | 6.70 | 6.48 | 8.69 | 9.81 | 6.46 | 6.37 | 6.02 |
| Total assets | 20.33 | 18.61 | 22.93 | 24.00 | 20.90 | 16.40 | 14.99 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.06 | 0.06 | 0.09 | 0.27 | 4.22 | 1.87 | 0.02 |
| Net cash from operating activities | 2.15 | 2.69 | (0.03) | (1.71) | (1.26) | 4.84 | 2.95 |
| Net cash from investing activities | (2.66) | 1.53 | 0.41 | (0.08) | (4.97) | (2.16) | (1.66) |
| Net cash from financing activities | 0.99 | (4.21) | (0.41) | 1.61 | 2.27 | (0.33) | 0.55 |
| Net change in cash | 0.48 | 0.00 | (0.03) | (0.17) | (3.95) | 2.35 | 1.85 |
| Closing cash | 0.63 | 0.06 | 0.09 | 0.20 | 0.88 | 4.86 | 2.05 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +7.9% | -15.0% | -22.9% | -27.6% | +53.9% | +36.7% | - |
| EBITDA growth | +1209.1% | +116.9% | -123.9% | -23.0% | +18.5% | +14.6% | - |
| PBT growth | +9998.0% | +25.7% | - | -65.9% | +54.4% | +17.4% | +54.8% |
| Net income growth | +106.7% | +27.1% | -352.6% | -60.1% | +16.3% | -23.6% | - |
| Revenue CAGR (3Y) | -10.9% | -22.0% | -4.9% | +15.0% | +29.8% | +13.9% | +16.5% |
| EBITDA CAGR (3Y) | -19.1% | -68.5% | - | +1.5% | +20.5% | +2.5% | +8.8% |
| Profitability & leverage | |||||||
| Net income margin | +0.3% | -4.1% | -4.6% | +1.7% | +3.5% | +3.2% | +3.7% |
| Return on capital employed | +3.4% | -3.0% | -4.4% | +6.6% | +13.1% | +13.5% | +18.7% |
| Return on net worth | +0.6% | -7.8% | -9.5% | +3.9% | +10.7% | +9.0% | +14.8% |
| Debt / equity | 0.51 | 0.57 | 0.63 | 0.51 | 0.37 | 0.30 | 0.28 |
| Long-term debt / equity | 0.04 | 0.06 | 0.05 | 0.04 | 0.03 | 0.00 | 0.01 |
| Interest cover | 115.22 | -93.98 | -51.79 | 42.22 | 17.31 | 20.85 | 21.56 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.62 | 1.61 | 2.02 | 2.91 | 4.38 | 2.99 | 2.20 |
| Inventory turnover | 5.10 | 4.26 | 3.24 | 4.56 | 14.75 | 16.86 | 11.32 |
| Debtors turnover | 5.33 | 5.00 | 6.81 | 8.61 | 9.81 | 6.61 | 6.34 |
| EPS (₹) | 0.17 | (2.31) | (3.07) | 1.47 | 4.24 | 2.44 | 2.14 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 28.80 | 28.51 | 30.87 | 33.87 | 32.60 | 28.29 | 25.75 |
Similar companies to Link Pharma
Link Pharma has 3 listed similar companies in our database, 2 of them funded. They include Laurus Labs, Symbiotec and SeQuent.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| lauruslabs.com | 2005 | Hyderabad, India | $229.73M | 6,035 | Pharmaceutical and biotechnology company | |
| symbiotec.in | 2002 | Indore, India | $61.01M | 1,822 | Non-sterile steroid hormone-based APIs and intermediates are manufactured. | |
| sequent.in | 2002 | Bengaluru, India | APIs are developed and manufactured for therapeutic areas. |
Detailed similar companies of Link Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Link Pharma (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Link Pharma
Complete news archive for Link Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Link Pharma
Link Pharma was founded in 1986.
Link Pharma is headquartered in Vadodara, India. It is registered at Vadodara, Gujarat, India.
Satish Thakur is the CEO of Link Pharma, as recorded in our data.
Link Pharma has 83 employees.
The primary company behind Link Pharma, Link Pharmachem Limited, reported revenue of ₹27.63 Cr for FY 2026, up 8% year on year.
Link Pharma was established in 1986 in Vadodara, India, within the chemical and pharmaceutical sector. Active pharmaceutical ingredients (APIs) and specialty chemicals are developed and manufactured by the company. Operations include production of compounds such as chlorine, oleum, chlorosulphonic acid, sulphuric acid, and sulfur chlorides. Services focus on these areas to support industrial needs in the region.
Link Pharma's top competitors include Laurus Labs, Symbiotec and SeQuent.
Link Pharma offers Pharma Intermediates, Agro Intermediates, Veterny Intermediates, Cosmetics Intermediates, and Fragrance Intermediates.
Yes, Link Pharma is publicly traded on BSE under the ticker symbol LINKPH.
Link Pharma operates through Link Pharmachem Limited.
The legal entities of Link Pharma currently have 7 directors, including Rishikesh Satish Thakur, Satish Ganpatrao Thakur, Rachna Manav Ghai and others.